BioInvent International AB   Report issue

For profit Phase 1 Phase 2
Founded: Lund Sweden (1996)

Organization Overview

First Clinical Trial
2007
NCT00612196
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BioInvent International AB

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 2)

Cardiovascular Diseases (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Medulloblastoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neuroblastoma (Phase 2)

Rhabdomyosarcoma (Phase 2)

Rhabdomyosarcoma, Alveolar (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Smoldering Multiple Myeloma (Phase 2)

Thromboembolism (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 17
  • # of Trial APIs: 16